Clinical Evidence Concern Over New COPD Update
There has been some criticism of the recent update to COPD management guidelines published by GOLD, with concern over the how much of the changes are based on clinical evidence.
You may also be interested in...
Chiesi's triple combination therapy for COPD, Trimbow, has secured its first approval globally after winning a positive recommendation from the CHMP for its use in Europe – but analysts expect a respiratory partner will be required to launch the product.
Sunovion has secured US rights to Novartis's respiratory inhalers, and will cash in on Novartis's FLAME data in COPD patients which recently helped change treatment guidelines.
New guidelines for the treatment of COPD could change the way this serious condition is managed, with knock-on effects for pharma companies with respiratory franchises.